According to a recent study, germline BRCA1/2 status did not affect prognosis. However, outcomes differed by immunohistochemistry (IHC) subtype as follows:
- Triple negative disease: overall and progression free survival was better than expected (compared to BRCA negative patients)
- Hormone receptor+/HER-: progression free survival was lower than expected (compared to BRCA negative patients)
Use the link in bio to learn more!
Reference: Mailliez, et al. Int J Cancer. 2023;152(5):921-931. PMID: 36161271.